| Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications M Galoppin, S Kari, S Soldati, A Pal, M Rival, B Engelhardt, A Astier, ... Brain Communications 4 (4), fcac171, 2022 | 36 | 2022 |
| Biological markers in early multiple sclerosis: the paved way for radiologically isolated syndrome M Rival, M Galoppin, E Thouvenot Frontiers in Immunology 13, 866092, 2022 | 14 | 2022 |
| Chronic neuroleptic‐induced parkinsonism examined with positron emission tomography M Galoppin, P Berroir, JP Soucy, Y Suzuki, GJ Lavigne, JF Gagnon, ... Movement Disorders 35 (7), 1189-1198, 2020 | 5 | 2020 |
| CD138 as a specific CSF biomarker of multiple sclerosis G Hinsinger, L Du Trieu De Terdonck, S Urbach, N Salvetat, M Rival, ... Neurology: Neuroimmunology & Neuroinflammation 11 (3), e200230, 2024 | 2 | 2024 |
| CITE-seq reveals inhibition of NF-kB pathway in B cells from vitamin D-treated multiple sclerosis patients M Galoppin, M Rival, A Louis, S Kari, S Soldati, B Engelhardt, A Astier, ... bioRxiv, 2023.09. 25.559400, 2023 | 1 | 2023 |
| Syndecan-1 as specific cerebrospinal fluid biomarker of multiple sclerosis G Hinsinger, L Du Trieu de Terdonck, S Urbach, N Salvetat, M Rival, ... bioRxiv, 2023.05. 10.540204, 2023 | | 2023 |
| BRAIN COMMUNICATIONS AIN COMMUNICATIONS M Galoppin, S Kari, S Soldati, A Pal, M Rival, B Engelhardt, A Astier, ... | | 2022 |
| Mechanisms of chronic neuroleptic-induced parkinsonism examined with positron emission tomography M Galoppin, P Berroir, J Soucy, E Stip, P Blanchet MOVEMENT DISORDERS 35, S39-S39, 2020 | | 2020 |
